YU163075A
(en)
|
1975-07-21 |
1982-05-31 |
Science Union & Cie |
Process for preparing new phenoxy derivatives
|
JP2969359B2
(ja)
|
1989-01-13 |
1999-11-02 |
武田薬品工業株式会社 |
環状アミン化合物
|
MX9100517A
(es)
|
1990-08-06 |
1992-04-01 |
Smith Kline French Lab |
Compuestos
|
ATE201669T1
(de)
|
1991-04-17 |
2001-06-15 |
Upjohn Co |
Substituierte (s)-3-phenylpiperidin derivate, deren herstellung und deren verwendung als dopamin autorezeptor antagonisten
|
US5236934A
(en)
*
|
1992-08-26 |
1993-08-17 |
E. I. Du Pont De Nemours And Company |
1,2,3,4-tetrahydroisoquinolines useful in the treatment of CNS disorders
|
JPH11501281A
(ja)
|
1993-06-18 |
1999-02-02 |
ユニバーシティ オブ シンシナティ |
神経ペプチドyアンタゴニスト及びアゴニスト
|
US5863903A
(en)
|
1994-03-09 |
1999-01-26 |
Novo Nordisk A/S |
Use of hydroxy alkyl piperidine and pyrrolidine compounds to treat diabetes
|
CA2187257A1
(en)
|
1995-10-12 |
1997-04-13 |
Enrique Luis Michelotti |
Aryl-substituted cycloalkanes and cycloalkenes and herbicidal use thereof
|
US5977134A
(en)
|
1996-12-05 |
1999-11-02 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US6316450B1
(en)
|
1997-07-11 |
2001-11-13 |
Smithkline Beecham P.L.C. |
Compounds
|
US6962998B2
(en)
|
2000-06-14 |
2005-11-08 |
Toray Industries, Inc. |
Processes for producing racemic piperidine derivative and for producing optically active piperidine derivative
|
US7148197B2
(en)
|
2000-08-24 |
2006-12-12 |
The Regents Of The University Of California |
Orally administered small peptides synergize statin activity
|
AR031152A1
(es)
|
2000-10-31 |
2003-09-10 |
Upjohn Co |
Tratamientos nuevos para el sindrome de piernas inquietas
|
JP2005518444A
(ja)
|
2002-02-22 |
2005-06-23 |
ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー |
アリールスルホン誘導体
|
US20040082641A1
(en)
|
2002-10-28 |
2004-04-29 |
Rytved Klaus Asger |
Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases
|
BR0316164A
(pt)
|
2002-11-12 |
2005-09-27 |
Pfizer Prod Inc |
Derivados de quinolina
|
SE0300010D0
(sv)
|
2003-01-07 |
2003-01-07 |
Astrazeneca Ab |
Novel Compounds
|
WO2004069792A2
(en)
|
2003-02-03 |
2004-08-19 |
Janssen Pharmaceutica N.V. |
Quinoline-derived amide modulators of vanilloid vr1 receptor
|
US20060293298A1
(en)
|
2003-04-10 |
2006-12-28 |
Bamford Mark J |
Compounds
|
WO2005000309A2
(en)
|
2003-06-27 |
2005-01-06 |
Ionix Pharmaceuticals Limited |
Chemical compounds
|
JP2007538085A
(ja)
|
2004-05-17 |
2007-12-27 |
アカディア ファーマシューティカルズ インコーポレイティド |
アンドロゲン受容体モジュレーターおよびそれを用いて疾患を治療する方法
|
WO2006049597A1
(en)
|
2004-10-27 |
2006-05-11 |
Avanir Pharmaceuticals |
Amino acid-derived compounds as modulators of the reverse cholesterol transport
|
KR20080025190A
(ko)
|
2005-06-30 |
2008-03-19 |
프로시디온 리미티드 |
G-단백질 결합된 수용체 효능제
|
GB0514812D0
(en)
|
2005-07-19 |
2005-08-24 |
Glaxo Group Ltd |
Compounds
|
DE102005044817A1
(de)
*
|
2005-09-20 |
2007-03-22 |
Sanofi-Aventis Deutschland Gmbh |
Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
|
EP1968961A2
(en)
|
2005-12-21 |
2008-09-17 |
Decode Genetics EHF |
Biaryl nitrogen heterocycle inhibitors of lta4h for treating inflammation
|
WO2007097289A1
(ja)
|
2006-02-20 |
2007-08-30 |
Takeda Pharmaceutical Company Limited |
新規医薬
|
US7834178B2
(en)
|
2006-03-01 |
2010-11-16 |
Bristol-Myers Squibb Company |
Triazine 11-beta hydroxysteroid dehydrogenase type 1 inhibitors
|
US9187485B2
(en)
|
2007-02-02 |
2015-11-17 |
Baylor College Of Medicine |
Methods and compositions for the treatment of cancer and related hyperproliferative disorders
|
CA2690378A1
(en)
|
2007-06-25 |
2008-12-31 |
Amgen Inc. |
Phthalazine compounds, compositions and methods of use
|
WO2009143633A1
(en)
|
2008-05-30 |
2009-12-03 |
Institut De Recherches Cliniques De Montreal |
Pcsk9 inhibitors and methods of use thereof
|
US8324385B2
(en)
|
2008-10-30 |
2012-12-04 |
Madrigal Pharmaceuticals, Inc. |
Diacylglycerol acyltransferase inhibitors
|
KR20120064717A
(ko)
|
2009-10-01 |
2012-06-19 |
카딜라 핼쓰캐어 리미티드 |
이상지질혈증 및 관련된 질병의 치료를 위한 화합물
|
EP2618826B1
(en)
|
2010-09-20 |
2016-04-13 |
A.Carlsson Research AB |
Phenylpiperidine compounds for the treatment of dementia
|
JOP20200043A1
(ar)
|
2011-05-10 |
2017-06-16 |
Amgen Inc |
طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
|
PT2707361T
(pt)
*
|
2011-05-10 |
2017-11-28 |
Gilead Sciences Inc |
Compostos heterocíclicos fusionados como moduladores do canal de sódio
|
CN107243078A
(zh)
|
2012-05-25 |
2017-10-13 |
克塔巴西斯制药有限公司 |
使前蛋白转化酶枯草溶菌素/kexin 9型(pcsk9)减少的方法
|
US20150051144A1
(en)
|
2012-06-25 |
2015-02-19 |
Cadila Healthcare Limited |
Compounds for the treatment of dyslipidemia and other diseases
|
CN103602337B
(zh)
|
2012-08-17 |
2015-04-29 |
石家庄诚志永华显示材料有限公司 |
环己烷衍生物及其制备方法与应用
|
WO2014101120A1
(en)
|
2012-12-28 |
2014-07-03 |
Merck Sharp & Dohme Corp. |
Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
|
EP2956154A4
(en)
|
2013-02-15 |
2016-07-27 |
Srx Cardio Llc |
TYPE 9 (PCSK9) PROPYTEIN CONVERTASE SUBTILISINE / KEXINE PROPAGINE CONVERTASE BINDING LIGANDS FOR USE IN MODULATION OF SERIES LEVELS OF LOW DENSITY LIPOPROTEIN (LDL)
|
US10287317B2
(en)
|
2013-02-15 |
2019-05-14 |
Srx Cardio, Llc |
Proprotein convertase subtilisin kexin type 9 (PCSK9) allosteric binding ligands to modulate serum low density lipoprotein (LDL) levels
|
ES2489815B1
(es)
|
2013-02-21 |
2015-08-10 |
Centro De Investigación Príncipe Felipe |
Nuevos p-terfenilos hexakis-sustituidos con grupos bilaterales para el tratamiento de la infección por el virus de la inmunodeficiencia humana tipo 1 (VIH-1) y otras enfermedades
|
AU2014235430A1
(en)
|
2013-03-15 |
2015-09-24 |
Amgen Inc. |
Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9 (PCSK9)
|
CA2904662A1
(en)
|
2013-03-15 |
2014-09-25 |
Shifa Biomedical Corporation |
Anti-pcsk9 compounds and methods for the treatment and/or prevention of cardiovascular diseases
|
WO2015024016A2
(en)
|
2013-08-16 |
2015-02-19 |
Duke University |
2-piperidinyl substituted n,3-dihydroxybutanamides
|
WO2015058129A1
(en)
|
2013-10-17 |
2015-04-23 |
Blueprint Medicines Corporation |
Compositions useful for treating disorders related to kit
|
WO2016029037A1
(en)
|
2014-08-21 |
2016-02-25 |
Srx Cardio, Llc |
Composition and methods of use of small molecules as binding ligands for the modulation of proprotein convertase subtilisin/kexin type 9(pcsk9) protein activity
|
US20170267689A1
(en)
|
2014-08-25 |
2017-09-21 |
The Governors Of The University Of Alberta |
Stimuli-switchable moieties, monomers and polymers incorporating stimuli-switchable moieties, and methods of making and using same
|
WO2016107602A1
(zh)
|
2015-01-01 |
2016-07-07 |
成都贝斯凯瑞生物科技有限公司 |
一类取代氮杂环衍生物及其应用
|
WO2016107603A1
(zh)
|
2015-01-01 |
2016-07-07 |
成都贝斯凯瑞生物科技有限公司 |
取代氮杂环衍生物及其应用
|
EP3337497B1
(en)
|
2015-08-21 |
2023-07-12 |
SRX Cardio, LLC |
Composition and methods of use of novel phenylalanine small organic compounds to directly modulate pcsk9 protein activity
|
EP3337564A4
(en)
|
2015-08-21 |
2019-01-23 |
Portola Pharmaceuticals, Inc. |
COMPOSITION AND METHOD FOR THE USE OF TETRAHYDROISOCHINOLINE SMALL MOLECULES FOR THE BINDING AND MODULATION OF PCSK9 PROTEIN ACTIVITY
|
US10568882B2
(en)
|
2015-08-21 |
2020-02-25 |
Srx Cardio, Llc |
Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators and their use
|
ES2879995T3
(es)
|
2015-12-10 |
2021-11-23 |
Ptc Therapeutics Inc |
Métodos para el tratamiento de la enfermedad de Huntington
|
WO2017147328A1
(en)
|
2016-02-23 |
2017-08-31 |
Portola Pharmaceuticals, Inc. |
Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)
|
JP2019524781A
(ja)
|
2016-08-03 |
2019-09-05 |
ニューロポア セラピーズ インコーポレイテッド |
Tlr2二量体化調節剤としての脂質置換アミノ1,2−ジオール化合物および脂質置換アミノ1,3−ジオール化合物
|
US11091466B2
(en)
|
2017-03-17 |
2021-08-17 |
Cardio Therapeutics Pty Ltd |
Heterocyclic inhibitors of PCSK9
|
WO2020252383A2
(en)
|
2019-06-14 |
2020-12-17 |
Srx Cardio, Llc |
Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (pcsk9)
|
US20220193058A1
(en)
|
2020-12-16 |
2022-06-23 |
Srx Cardio, Llc |
Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (pcsk9)
|